Mablink Breaks into ADC Space with $30M for Improved Linker Tech

France-based biotech Mablink secured $30 million (€31 million EUR) to develop next-generation antibody-drug conjugates for the treatment of cancer.

The finances will be used to advance its lead ADC candidate MBK-103 into the clinic and support the development of a pipeline of ADCs with the company’s proprietary platform, its PSARlink masking technology.